Keith Kummerfeld Biography and Net Worth

Insider of Arcturus Therapeutics

Keith C. Kummerfeld is currently working as the Principal Accounting Officer & VP-Finance at Arcturus Therapeutics Ltd. He previously worked as the Corporate Controller at Ikanos Communications, Inc. and as the Senior Vice President-Finance & Controller at Arcturus Therapeutics Holdings, Inc.

What is Keith C. Kummerfeld's net worth?: The estimated net worth of Keith C. Kummerfeld is at least $6.49 thousand as of July 14th, 2023. Kummerfeld owns 950 shares of Arcturus Therapeutics stock worth more than $6,489 as of December 4th. This net worth approximation does not reflect any other assets that Kummerfeld may own. Learn More about Keith C. Kummerfeld's net worth.
How do I contact Keith C. Kummerfeld?: The corporate mailing address for Kummerfeld and other Arcturus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. Arcturus Therapeutics can also be reached via phone at (858) 900-2660 and via email at [email protected]. Learn More on Keith C. Kummerfeld's contact information.
Has Keith C. Kummerfeld been buying or selling shares of Arcturus Therapeutics?: Keith C. Kummerfeld has not been actively trading shares of Arcturus Therapeutics during the last ninety days. Most recently, Keith C. Kummerfeld sold 6,968 shares of the business's stock in a transaction on Friday, July 14th. The shares were sold at an average price of $35.00, for a transaction totalling $243,880.00. Following the completion of the sale, the insider now directly owns 950 shares of the company's stock, valued at $33,250. Learn More on Keith C. Kummerfeld's trading history.
Who are Arcturus Therapeutics' active insiders?: Arcturus Therapeutics' insider roster includes Pad Chivukula (COO), and Keith Kummerfeld (Insider). Learn More on Arcturus Therapeutics' active insiders.

Keith C. Kummerfeld Insider Trading History at Arcturus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/14/2023	Sell	6,968	$35.00	$243,880.00	950
4/18/2023	Sell	6,968	$28.18	$196,358.24	950
6/12/2020	Buy	450	$33.33	$14,998.50	950

Keith C. Kummerfeld Buying and Selling Activity at Arcturus Therapeutics

Arcturus Therapeutics Company Overview

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Today's Range

Now: $6.83

$6.47

$6.85

50 Day Range

MA: $12.70

$5.90

$23.16

2 Week Range

Now: $6.83

$5.85

$24.17

Volume

666,188 shs

Average Volume

895,528 shs

Market Capitalization

$194.04 million

P/E Ratio

N/A

Dividend Yield